首页 | 本学科首页   官方微博 | 高级检索  
     


Extracellular vesicles derived from injured vascular tissue promote the formation of tertiary lymphoid structures in vascular allografts
Authors:M  lanie Dieud  ,Julie Turgeon,Annie Karakeussian Rimbaud,D  borah Beillevaire,Shijie Qi,Nathalie Patey,Louis A. Gaboury,   ric Boilard,Marie‐Jos  e H  bert
Affiliation:Mélanie Dieudé,Julie Turgeon,Annie Karakeussian Rimbaud,Déborah Beillevaire,Shijie Qi,Nathalie Patey,Louis A. Gaboury,Éric Boilard,Marie‐Josée Hébert
Abstract:Tertiary lymphoid structures (TLS) accumulate at sites of chronic injury where they function as an ectopic germinal center, fostering local autoimmune responses. Vascular injury leads to the release of endothelial‐derived apoptotic exosome‐like vesicles (ApoExo) that contribute to rejection in transplanted organs. The purpose of the study was to evaluate the impact of ApoExo on TLS formation in a model of vascular allograft rejection. Mice transplanted with an allogeneic aortic transplant were injected with ApoExo. The formation of TLS was significantly increased by ApoExo injection along with vascular remodeling and increased levels of antinuclear antibodies and anti‐perlecan/LG3 autoantibodies. ApoExo also enhanced allograft infiltration by γδT17 cells. Recipients deficient in γδT cells showed reduced TLS formation and lower autoantibodies levels following ApoExo injection. ApoExo are characterized by proteasome activity, which can be blocked by bortezomib. Bortezomib treated ApoExo reduced the recruitment of γδT17 cells to the allograft, lowered TLS formation, and reduced autoantibody production. This study identifies vascular injury‐derived extracellular vesicles (ApoExo), as initiators of TLS formation and demonstrates the pivotal role of γδT17 in coordinating TLS formation and autoantibody production. Finally, our results suggest proteasome inhibition with bortezomib as a potential option for controlling TLS formation in rejected allografts.
Keywords:antigen presentation/ recognition  autoantibody  basic (laboratory) research/science  cell death: apoptosis  immunobiology  rejection: vascular  vasculopathy
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号